Signaling Pathways - Vascular Disrupting Agents (VDA) - DOT1L - CRM1 - DPP-4
清除全部
- B3941 Talabostat mesylate2 CitationTarget: DPP-4Summary: DPP4抑制剂
- B1581 EPZ004777 HClTarget: DOT1LSummary: DOT1L抑制剂
- B1463 KPT-276Target: nuclear export|CRM1Summary: CRM1抑制剂
- B2298 Plinabulin (NPI-2358)中文名: 普那布林Target: Vascular Disrupting Agents (VDA)Summary: 血管破坏剂
- A8650 Saxagliptin中文名: 沙格列汀Target: DPP-4Summary: DPP4抑制剂
- A3865 Teneligliptin hydrobromide中文名: 氢溴酸替格列汀Target: DPP-4Summary: DDP4抑制剂
- A4170 EPZ004777Target: DOT1LSummary: DOT1L抑制剂
- A4038 Alogliptin (SYR-322)1 Citation中文名: 阿格列汀Target: DPP-4Summary: DPP-4抑制剂
- A4036 Sitagliptin phosphate monohydrate5 Citation中文名: 磷酸西他列汀一水合物Target: DPP-4Summary: DPP-4抑制剂
- A4166 EPZ56761 CitationTarget: DOT1LSummary: DOT1L抑制剂